Making The Case For A Legislative Deal On Drug Pricing
Executive Summary
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
You may also be interested in...
Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
With US Senate Wins In Georgia, Democrats Gain Path For Rx Price Reform, But It May Be Lower Priority
Razor-thin majorities in both chambers of Congress mean Democrats can’t enact a bold agenda, and the pandemic and attendant recession mean that the initial legislative focus won’t be on Rx issues.